Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

9.78
+0.57006.19%
Post-market: 9.780.00000.00%19:30 EDT
Volume:1.76M
Turnover:17.03M
Market Cap:1.65B
PE:-5.76
High:9.86
Open:9.31
Low:9.31
Close:9.21
52wk High:11.66
52wk Low:4.35
Shares:168.65M
Float Shares:130.00M
Volume Ratio:1.24
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6972
EPS(LYR):-3.1619
ROE:-26.08%
ROA:-14.51%
PB:1.68
PE(LYR):-3.09

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
Vir Biotechnology, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
367
Office Location:
1800 Owens Street,Suite 900,San Francisco,California,United States
Website:
http://www.vir.bio
Zip Code:
94158
Phone:
415 906 4324
Fax:
- -
Introduction:
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Directors

Name
Position
Marianne De Backer
President, Chief Executive Officer and Director
Elliott Sigal
Independent Director
Janet Napolitano
Independent Director
Jeffrey S. Hatfield
Board Chair
Norbert Bischofberger
Independent Director
Ramy Farid
Independent Director
Robert More
Independent Director

Shareholders

Name
Position
Marianne De Backer
President, Chief Executive Officer and Director
Jason O byrne
Executive Vice President and Chief Financial Officer
Mark Eisner
Executive Vice President and Chief Medical Officer
Vanina de Verneuil
Executive Vice President, General Counsel and Corporate Secretary